Cantor Fitzgerald Predicts BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Bicara Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($2.50) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14).

Several other research firms have also commented on BCAX. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price target on the stock. Finally, TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Stock Performance

Shares of NASDAQ BCAX opened at $11.60 on Thursday. Bicara Therapeutics has a 1-year low of $11.51 and a 1-year high of $28.09. The firm’s 50-day moving average price is $17.08.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BCAX. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $31,000. SG Americas Securities LLC bought a new stake in Bicara Therapeutics during the 4th quarter valued at approximately $147,000. Cinctive Capital Management LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $229,000. Barclays PLC bought a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $255,000. Finally, Jane Street Group LLC bought a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.